Malaria and Sickle Cell Disease Treatment Market Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Treatment [Malaria and Sickle Cell Disease (SCD)], Route of Administration (Oral and

Malaria and Sickle Cell Disease Treatment Market Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Treatment [Malaria and Sickle Cell Disease (SCD)], Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)

The malaria and sickle cell disease treatment market is expected to grow from US$ 4.457 billion in 2022 to US$ 29.179 billion by 2030; it is estimated to grow at a CAGR of 26.5% from 2022 to 2030. The market for malaria and sickle cell disease treatment is growing due to the increasing prevalence of malaria and sickle cell disease and rising government initiatives to raise awareness about malaria and SCD. However, factors such as a counterfeit antimalarial drug and subsequent drug resistance are restraining the market growth.

Antimicrobial resistance can put the public at risk of many diseases, such as malaria. To overcome this challenge, the R&D of new medicines is considered the best strategy; as a result, the antimalarial and SCD drug/vaccine pipeline is becoming increasingly robust. Public-private partnerships are accelerating research activities related to the treatment of malaria and sickle cell disease. For instance, Medicines for Malaria Venture (MMV), a nonprofit organization, works with numerous pharmaceutical companies to reduce the burden of malaria by developing novel treatment options.

A few antimalarial and SCD drugs/vaccines that are under clinical development are mentioned in the table below:

Table 1. Malaria Drugs/Vaccine/Compounds Under Clinical Development
Drug Developer Clinical Trial Stage
Artefenomel Sanofi Phase IIb
KAE609 Novartis AG Phase IIb
KAF156 Novartis AG Phase IIb
DSM265 Takeda Pharmaceutical Company Phase IIa
SANARIA PfSPZ-GA1 Sanaria Phase II
SANARIA PfSPZ Vaccine – Radiation Attenuated PfSPZ Vaccine Sanaria Phase II
SANARIA PfSPZ-CVac Sanaria Phase II
MSP3-CRM-Vac4All Vac4All Phase I
Liver-Stage Antigen-3 (LSA3) Vac4All Phase IIa
Source: Company Website, The Insight Partners Analysis
Table 2. Sickle Cell Disease Drugs/Vaccine/Compounds Under Clinical Development
Drug Developer Clinical Trial Stage
Inclacumab Pfizer Phase III
Voxelotor Pfizer Phase III
GBT021601 Pfizer Phase II
PF-07209326 Pfizer Phase II
RG6107 Roche Phase II
GSK4172239D GSK Phase I
BEAM¬–101 Beam Therapeutics Phase I/II
HGB-206 Bluebird Bio, Inc. Phase I/II
HGB-210 Bluebird Bio, Inc. Phase III
ALXN1820 Alexion Phase II
NCT05714969 Takeda Pharmaceutical Company Limited Phase 2b
NCT03997760 Takeda Pharmaceutical Company Limited Phase I
Source: Company Website, The Insight Partners Analysis
9Therefore, the growing number of antimalarial and SCD drugs/vaccines that are under clinical development are expected to boost the market growth in the future.

The report segments the malaria and sickle cell disease treatment market as follows:

The malaria and sickle cell disease (SCD) treatment market is segmented on the basis of treatment, route of administration, distribution channel, and geography. Based on treatment, the market is divided into malaria and sickle cell disease. In terms of route of administration, the malaria and sickle cell disease (SCD) treatment market is divided into oral and parenteral. Based on distribution channel, the market is categorized into direct tender, hospital pharmacies, retail pharmacies, online pharmacies, and others. By geography, the malaria and sickle cell disease treatment market is segmented into North America (the US, Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and Rest of Asia Pacific), the Middle East & Africa (Saudi Arabia, the UAE, South Africa, Kenya, Tanzania, Rwanda, Nigeria, Ghana, Uganda, Angola, Cameroon, Senegal, Zambia, and Rest of the Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America).

Route of Administration-Based Insights

By route of administration, the malaria treatment market is bifurcated into oral and parenteral. In 2022, the oral segment held a larger market share, and the parenteral segment is estimated to record a faster CAGR during 2020–2030. Oral drug delivery is the most ideal and suitable route of drug administration as it offers high patient compliance, non-invasiveness, least sterility constraints, cost-effectiveness, flexibility in the design of dosage form, and ease in the manufacturing process. Benefits such as ease of administration and long-term cost efficiency are the major factors fueling the adoption of oral drugs.

Distribution Channel-Based Insights

Based on distribution channel, the malaria and sickle cell disease (SCD) treatment market is segmented into direct tender, hospital pharmacies, retail pharmacies, online pharmacies, and others. The direct tender segment held the largest market share in 2022. A tender is an offer to do specific duties or provide items for a fixed amount. In the first step of a tender procedure, contractors will be asked to submit sealed bids for construction or to offer particularly planned services or products within a specific time limit. The e-tendering procedure in India is designed to ensure that work for the government or a specific client is completed in a timely manner.

A few of the major primary and secondary sources referred to while preparing the report on the malaria and sickle cell disease treatment market are the World Health Organization (WHO), the US Census Bureau, and CDC, among others.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the malaria and sickle cell disease (SCD) treatment market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the global malaria and sickle cell disease (SCD) treatment market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution.